Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $89.7 million.

  • Heron Therapeutics' Total Current Liabilities rose 486.77% to $89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.7 million, marking a year-over-year increase of 486.77%. This contributed to the annual value of $91.5 million for FY2024, which is 1477.32% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Total Current Liabilities is $89.7 million, which was up 486.77% from $258.6 million recorded in Q2 2025.
  • Heron Therapeutics' Total Current Liabilities' 5-year high stood at $258.6 million during Q2 2025, with a 5-year trough of $71.1 million in Q4 2021.
  • In the last 5 years, Heron Therapeutics' Total Current Liabilities had a median value of $85.5 million in 2024 and averaged $94.7 million.
  • In the last 5 years, Heron Therapeutics' Total Current Liabilities plummeted by 3067.72% in 2021 and then skyrocketed by 22197.54% in 2025.
  • Over the past 5 years, Heron Therapeutics' Total Current Liabilities (Quarter) stood at $71.1 million in 2021, then grew by 15.9% to $82.4 million in 2022, then decreased by 3.24% to $79.7 million in 2023, then increased by 14.77% to $91.5 million in 2024, then decreased by 1.91% to $89.7 million in 2025.
  • Its last three reported values are $89.7 million in Q3 2025, $258.6 million for Q2 2025, and $88.6 million during Q1 2025.